Govindasamy Chandramohan, El Newehy Ahmed S, Hussein-Al-Ali Samer Hasan, Arulselvan Palanisamy, Bharathi Muruganantham, Parthasarathy Surya
Department of Community Health Sciences, College of Applied Medical Sciences, King Saud University, P.O. Box 10219, Riyadh 11433, Saudi Arabia.
Department of Chemistry, Faculty of Sciences, Isra University, Amman 11622, Jordan.
Int J Biol Macromol. 2024 Jun;270(Pt 2):132284. doi: 10.1016/j.ijbiomac.2024.132284. Epub 2024 May 10.
Liposomes and nanofibers have been implemented as efficacious vehicles for delivering anticancer drugs. With this view, this study explores the antiproliferative efficacy and apoptosis induction in leukemia cancer cells utilizing irinotecan-loaded liposome-embedded nanofibers fabricated from chitosan, a biological source. Specifically, we investigate the effectiveness of poly(ε-caprolactone) (PCL)/chitosan (CS) (core)/irinotecan (CPT)nanofibers (termed PCL-CS10 CPT), PCL/chitosan/irinotecan (core)/PCL/chitosan (shell) nanofibers (termed CS/CPT/PCL/CS), and irinotecan-coloaded liposome-incorporated PCL/chitosan-chitosan nanofibers (termed CPT@Lipo/CS/PCL/CS) in releasing irinotecan in a controlled manner and treating leukemia cancer. The fabricated formulations were characterized utilizing Fourier transform infrared analysis, transmission electron microscopy, scanning electron microscopy, dynamic light scattering, zeta potential, and polydispersity index. Irinotecan was released in a controlled manner from nanofibers filled with liposomes over 30 days. The cell viability of the fabricated nanofibrous materials toward Human umbilical vein endothelial cells (HUVECs) non-cancerous cells after 168 h was >98 % ± 1 %. The CPT@Lipo/CS/PCL/CS nanofibers achieved maximal cytotoxicity of 85 % ± 2.5 % against K562 leukemia cancer cells. The CPT@Lipo/CS/PCL/CS NFs exhibit a three-stage drug release pattern and demonstrate significant in vitro cytotoxicity. These findings indicate the potential of these liposome-incorporated core-shell nanofibers for future cancer therapy.
脂质体和纳米纤维已被用作递送抗癌药物的有效载体。基于此观点，本研究探索了利用由生物源壳聚糖制备的负载伊立替康的脂质体包埋纳米纤维对白血病癌细胞的抗增殖功效和凋亡诱导作用。具体而言，我们研究了聚（ε-己内酯）（PCL）/壳聚糖（CS）（核）/伊立替康（CPT）纳米纤维（称为PCL-CS10 CPT）、PCL/壳聚糖/伊立替康（核）/PCL/壳聚糖（壳）纳米纤维（称为CS/CPT/PCL/CS）以及负载伊立替康的脂质体掺入的PCL/壳聚糖-壳聚糖纳米纤维（称为CPT@Lipo/CS/PCL/CS）以可控方式释放伊立替康并治疗白血病癌症的效果。利用傅里叶变换红外分析、透射电子显微镜、扫描电子显微镜、动态光散射、zeta电位和多分散指数对制备的制剂进行了表征。伊立替康在30天内从充满脂质体的纳米纤维中以可控方式释放。制备的纳米纤维材料在168小时后对人脐静脉内皮细胞（HUVECs）非癌细胞的细胞活力>98%±1%。CPT@Lipo/CS/PCL/CS纳米纤维对K562白血病癌细胞的最大细胞毒性达到85%±2.5%。CPT@Lipo/CS/PCL/CS纳米纤维呈现出三阶段药物释放模式，并表现出显著的体外细胞毒性。这些发现表明这些脂质体掺入的核壳纳米纤维在未来癌症治疗中的潜力。
